Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | DHODH | Q02127 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304907 | 0.83 | TTK (0.68) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL553902 | 0.81 | NLRP3 (0.56) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL3042676 | 0.80 | NLRP3 (0.48) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL31436857 | 0.78 | NLRP3 (0.55) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL3045328 | 0.76 | CA12 (0.55) | DHODHMAPTRAB9ACYP1A2GAA | |
| SCHEMBL23581727 | 0.75 | NLRP3 (0.63) | NLRP3TTKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23581766 | 0.74 | NLRP3 (0.56) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL3344425 | 0.73 | NLRP3 (0.56) | NLRP3TTKAURKARPS6KB1DHODH | |
| SCHEMBL3343777 | 0.73 | NLRP3 (0.53) | NLRP3TTKAURKARPS6KB1ALDH1A1 | |
| SCHEMBL15064334 | 0.72 | NLRP3 (0.54) | NLRP3TTKAURKARPS6KB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | UNIV BROWN (US) | 2015-12-17 | — | — | US | disclosed |
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130190402-A1 | Methods Of Treating Autism With mGluR5 Antagonists | EMORY UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100210542-A1 | Methods of Treating Disorders with Group I mGluR Antagonists | NIH-DEITR | 2010-08-19 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7648993-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-23 | — | — | US | disclosed |
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-08-04 | — | — | US | disclosed |
| US-6916821-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| US-6890931-B2 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | OXTR, MECP2, GRM5 | NLRP3 4325/4885TTK 3514/4885AURKA 3016/4885 |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | HRH3, HRH4, HRH2 | NLRP3 1278/4885TTK 4513/4885AURKA 4487/4885 |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | NLRP3 4528/4885TTK 4078/4885AURKA 4809/4885 |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | NLRP3 3839/4885TTK 2849/4885AURKA 4210/4885 |
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | GRM5, GRIK5, GRIK4 | NLRP3 2284/4885TTK 3971/4885AURKA 4200/4885 |
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | GRM5, GRIK5, GRM2 | NLRP3 3774/4885TTK 4339/4885AURKA 4749/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | NLRP3 3871/4885TTK 2808/4885AURKA 4198/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | NLRP3 2178/4885TTK 4614/4885AURKA 3222/4885 |
| US-20100210542-A1 | Methods of Treating Disorders with Group I mGluR Antagonists | GRM5, GRIK5, GRM2 | NLRP3 3774/4885TTK 4339/4885AURKA 4749/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | NLRP3 3871/4885TTK 2808/4885AURKA 4198/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | NLRP3 3774/4885TTK 4339/4885AURKA 4749/4885 |
| US-20130190402-A1 | Methods Of Treating Autism With mGluR5 Antagonists | GRM5, GRIK5, GRIK4 | NLRP3 2284/4885TTK 3971/4885AURKA 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.